Hutch News

Hutch News

Stories tagged 'ASH 2017'

Promising results in trial of engineered T cells in high-risk leukemia

High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia

July 17, 2017 | By Susan Keown / Fred Hutch News Service

Most patients with recurrent chronic lymphocytic leukemia who were enrolled in a small, early- phase trial saw their advanced tumors shrink or even disappear after an infusion of genetically engineered immune cells. Dr. Cameron Turtle, one of the study’s leaders, presented the results on Saturday at the 2016 annual meeting of the American Society of Hematology in San Diego.

View story >


Bringing a leukemia treatment back to life with precision medicine

New research writes latest chapter in one drug's story

June 27, 2017 | by Susan Keown / Fred Hutch News Service

The leukemia drug gemtuzumab ozogamicin (Mylotarg) was pulled from the market seven years after initial approval. Now, new evidence may be bringing it back to life to treat a specific group of patients.

View story >


The quest to better understand the deadliest childhood leukemia

Oncologists are beginning to leverage unique genomic characteristics of pediatric AML to improve treatment and prognosis

Dec. 7, 2016 | By Sabrina Richards / Fred Hutch News Service

Acute myeloid leukemia is the deadliest leukemia among children. Only 60 percent of patients will achieve long-term remission. But scientists see change on the horizon.

View story >


Fred Hutch opens first-of-its kind Bezos Family Immunotherapy Clinic

Clinic will allow researchers to conduct twice as many immunotherapy trials, enable intensive patient monitoring to improve experimental therapies

Nov. 1, 2016 | By Fred Hutch News Service

The new clinic will allow researchers to conduct twice as many immunotherapy trials and enable intensive patient monitoring to improve experimental therapies.

View story >


Patients with advanced lymphoma in remission after T-cell therapy

New study: 7 of 11 trial participants who got two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission

Sept. 7, 2016 | By Susan Keown / Fred Hutch News Service

Seven of 11 trial participants who got a two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission, a new study found.

View story >


93 percent of advanced leukemia patients in remission after immunotherapy

‘Exciting’ but early results from trial of engineered immune cells

April 25, 2016 | By Susan Keown / Fred Hutch News Service

After her immune cells were genetically engineered to target her cancer, Kristin Kleinhofer's leukemia disappeared. The trial was her and her family's 'last hope'.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.